Primary hyperparathyroidism in women: Medical and surgical treatments

Jennifer Wojtowicz, Kresimira Milas

Research output: Contribution to journalArticle

Abstract

Primary hyperparathyroidism (HPT) occurs in 2% of people over the age of 55. Women are affected two to three times more often then men. Postmenopausal women are at the greatest risk. The advent of the multichannel, routine screening of serum chemistries in the 1970s led to a dramatic increase in the detection of hypercalcemia and the diagnosis of underlying HPT. The recognition of HPT and its evolving clinical presentation has also been influenced by greater attention devoted over the last two decades to the screening for bone disease. Chronic parathyroid hormone excess stimulates bone remodeling and ultimately activates osteoclast-mediated destruction of bone. Medical treatment options are evolving for osteoporosis in HPT. Treatments that may improve bone density in HPT include bisphosphonates, estrogen, selective estrogen receptor modulators, and surgery.

Original languageEnglish (US)
Pages (from-to)143-147
Number of pages5
JournalClinical Reviews in Bone and Mineral Metabolism
Volume3
Issue number2
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Primary Hyperparathyroidism
Hyperparathyroidism
Selective Estrogen Receptor Modulators
Bone Remodeling
Bone Diseases
Diphosphonates
Hypercalcemia
Osteoclasts
Therapeutics
Parathyroid Hormone
Bone Density
Osteoporosis
Estrogens
Bone and Bones
Serum

Keywords

  • Bisphosphonates
  • Hyperparathyroidism
  • Osteoporosis
  • Postmenopausal
  • Selective estrogen receptor modulators (SERMs) parathyroidectomy

ASJC Scopus subject areas

  • Endocrinology

Cite this

Primary hyperparathyroidism in women : Medical and surgical treatments. / Wojtowicz, Jennifer; Milas, Kresimira.

In: Clinical Reviews in Bone and Mineral Metabolism, Vol. 3, No. 2, 06.2005, p. 143-147.

Research output: Contribution to journalArticle

Wojtowicz, Jennifer ; Milas, Kresimira. / Primary hyperparathyroidism in women : Medical and surgical treatments. In: Clinical Reviews in Bone and Mineral Metabolism. 2005 ; Vol. 3, No. 2. pp. 143-147.
@article{064ec1464b284bfea7ffe8cd3558b1c2,
title = "Primary hyperparathyroidism in women: Medical and surgical treatments",
abstract = "Primary hyperparathyroidism (HPT) occurs in 2{\%} of people over the age of 55. Women are affected two to three times more often then men. Postmenopausal women are at the greatest risk. The advent of the multichannel, routine screening of serum chemistries in the 1970s led to a dramatic increase in the detection of hypercalcemia and the diagnosis of underlying HPT. The recognition of HPT and its evolving clinical presentation has also been influenced by greater attention devoted over the last two decades to the screening for bone disease. Chronic parathyroid hormone excess stimulates bone remodeling and ultimately activates osteoclast-mediated destruction of bone. Medical treatment options are evolving for osteoporosis in HPT. Treatments that may improve bone density in HPT include bisphosphonates, estrogen, selective estrogen receptor modulators, and surgery.",
keywords = "Bisphosphonates, Hyperparathyroidism, Osteoporosis, Postmenopausal, Selective estrogen receptor modulators (SERMs) parathyroidectomy",
author = "Jennifer Wojtowicz and Kresimira Milas",
year = "2005",
month = "6",
doi = "10.1385/BMM:3:2:143",
language = "English (US)",
volume = "3",
pages = "143--147",
journal = "Clinical Reviews in Bone and Mineral Metabolism",
issn = "1534-8644",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Primary hyperparathyroidism in women

T2 - Medical and surgical treatments

AU - Wojtowicz, Jennifer

AU - Milas, Kresimira

PY - 2005/6

Y1 - 2005/6

N2 - Primary hyperparathyroidism (HPT) occurs in 2% of people over the age of 55. Women are affected two to three times more often then men. Postmenopausal women are at the greatest risk. The advent of the multichannel, routine screening of serum chemistries in the 1970s led to a dramatic increase in the detection of hypercalcemia and the diagnosis of underlying HPT. The recognition of HPT and its evolving clinical presentation has also been influenced by greater attention devoted over the last two decades to the screening for bone disease. Chronic parathyroid hormone excess stimulates bone remodeling and ultimately activates osteoclast-mediated destruction of bone. Medical treatment options are evolving for osteoporosis in HPT. Treatments that may improve bone density in HPT include bisphosphonates, estrogen, selective estrogen receptor modulators, and surgery.

AB - Primary hyperparathyroidism (HPT) occurs in 2% of people over the age of 55. Women are affected two to three times more often then men. Postmenopausal women are at the greatest risk. The advent of the multichannel, routine screening of serum chemistries in the 1970s led to a dramatic increase in the detection of hypercalcemia and the diagnosis of underlying HPT. The recognition of HPT and its evolving clinical presentation has also been influenced by greater attention devoted over the last two decades to the screening for bone disease. Chronic parathyroid hormone excess stimulates bone remodeling and ultimately activates osteoclast-mediated destruction of bone. Medical treatment options are evolving for osteoporosis in HPT. Treatments that may improve bone density in HPT include bisphosphonates, estrogen, selective estrogen receptor modulators, and surgery.

KW - Bisphosphonates

KW - Hyperparathyroidism

KW - Osteoporosis

KW - Postmenopausal

KW - Selective estrogen receptor modulators (SERMs) parathyroidectomy

UR - http://www.scopus.com/inward/record.url?scp=23844541361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844541361&partnerID=8YFLogxK

U2 - 10.1385/BMM:3:2:143

DO - 10.1385/BMM:3:2:143

M3 - Article

AN - SCOPUS:23844541361

VL - 3

SP - 143

EP - 147

JO - Clinical Reviews in Bone and Mineral Metabolism

JF - Clinical Reviews in Bone and Mineral Metabolism

SN - 1534-8644

IS - 2

ER -